Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)

This prospective study compares two types of stem cell transplant strategies — one using a donor's cells (allogeneic HSCT) versus the patient's own cells (autologous HSCT) — for patients with a type of T-cell lymphoma (PTCL) that only partially responded to first-line chemotherapy, to determine which approach leads to better long-term outcomes. **You may be eligible if...** - You are between 18 and 70 years old - You have a confirmed diagnosis of specific types of PTCL (such as PTCL-NOS, ALK-negative ALCL, or follicular T-cell lymphoma) - You achieved a partial response (not a full response) after 6 cycles of standard chemotherapy - Your heart, lung, liver, and kidney function meet required levels - A suitable stem cell donor is available (for the allogeneic group) - Your expected survival is greater than 12 weeks **You may NOT be eligible if...** - Your lymphoma is at an early stage (Stage I) - You have another cancer in the past 5 years (with limited exceptions) - You have an active infection (including HIV, active tuberculosis, or active hepatitis B or C) - You have poorly controlled heart problems - You are pregnant or breastfeeding - Your lymphoma has spread to the central nervous system (brain or spinal cord) - You have previously received a PD-1 inhibitor (a type of immune checkpoint drug) Talk to your doctor to see if this trial is right for you.